Article

Spreading agent given marketing exclusivity

Irvine, CA-The FDA is giving ISTA Pharmaceuticals Inc. 3 years of marketing exclusivity for hyaluronidase for injection (Vitrase) for use as a spreading agent to facilitate the dispersion and absorption of other injected drugs.

Irvine, CA-The FDA is giving ISTA Pharmaceuticals Inc. 3 years of marketing exclusivity for hyaluronidase for injection (Vitrase) for use as a spreading agent to facilitate the dispersion and absorption of other injected drugs.

The marketing exclusivity means the FDA will not approve any other hyaluronidase in the United States until May 5, 2007. The compound previously was on the FDA's list of drug shortages.

ISTA Pharmaceuticals has made the drug available to physicians free of charge while it prepares for approval of a smaller 150 USP units/ml vial that is expected to be more convenient and cost effective. The company expects approval of the smaller unit size later this year with a full marketing launch in early 2005.

"We are proud of our work with Allergan and pleased that our new agreement allows us to continue our relationship," said ISTA President and CEO Vicente Anido Jr. "For ISTA, our reacquisition of U.S. marketing rights to Vitrase for the posterior segment of the eye is another important step in our growth as a specialty pharmaceutical company focused on ophthalmology."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
© 2025 MJH Life Sciences

All rights reserved.